|
Before co-founding Epitomics, Mr. Zhu served as a research scientist at Bayer Corporation where he developed a series of high throughput assays for anti cancer drug screen and contributed to the discovery of several drug candidates. Prior to Bayer, Mr. Zhu was a senior associate specialist at UCSF where he pioneered rabbit monoclonal antibody technology (created new rabbit fusion partner 240E-W) and established the high throughput system for rabbit hybridoma generation that has become the core technology of Epitomics, Inc. Using this technology, he led his team developing a large number of high quality rabbit MAbs and identifying a number of cancer specific molecules. He received his M.S. in Cell Biology at Xiamen University, China. Mr. Zhu was a Senior Research Fellow at the Institute of Pathology of Zhejiang Medical University where he began his monoclonal antibody study. Mr. Zhu was a visiting scientist at the Institute of Pharmacological Sciences of Milan, Italy, and subsequently at the Gladstone Cardiovascular Disease Institute at UCSF. Mr. Zhu is the author of more than 20 scientific publications and co-inventor of several patents. | 